ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

LCAV (MM)

5.37
0.00 (0.00%)
30 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
(MM) NASDAQ:LCAV NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.37 0 01:00:00

LCA-Vision Reports First Quarter Procedure Volume of 14,898

02/04/2014 12:00pm

PR Newswire (US)


(MM) (NASDAQ:LCAV)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more (MM) Charts.

CINCINNATI, April 2, 2014 /PRNewswire/ -- LCA-Vision Inc. (NASDAQ: LCAV), a leading provider of laser vision correction services under the LasikPlus® brand, today reported that 14,898 procedures were performed during the first quarter of 2014, a decline of 8% from the 16,272 procedures performed during the first quarter of 2013. 

Michael J. Celebrezze, chief executive officer of LCA-Vision, said, "As we previously disclosed, procedure volume got off to a sluggish start during the quarter. We are disappointed with the decline in volume this quarter although inclement weather was certainly a factor in a number of our service areas, as 27 centers were closed a total of 56 days, while 23 centers were partially closed for an additional 44 days during the quarter."  

About LCA-Vision Inc./LasikPlus®
LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, operates 60 LasikPlus® vision centers in the U.S., including 51 full-service LasikPlus® fixed-site laser vision correction centers and 9 pre- and post-operative LasikPlus® satellite centers. LCA-Vision has performed more than 1.3 million procedures since FDA approval of photorefractive keratectomy (PRK) in late 1995.

For Additional Information




Company Contact:

Investor Relations Contact:

Barb Kise, LCA-Vision

Kim Sutton Golodetz, LHA

513-792-9292

212-838-3777


kgolodetz@lhai.com


@LHA_IR_PR

SOURCE LCA-Vision, Inc.

Copyright 2014 PR Newswire

1 Year (MM) Chart

1 Year (MM) Chart

1 Month (MM) Chart

1 Month (MM) Chart

Your Recent History

Delayed Upgrade Clock